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NOTES FROM THE FIELD
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Tuberculosis (TB) is a disease associated with inequal-
ity, and wise investment of economic resources is con-
sidered critical to its control. Panama has recently se-
cured its status as an upper-middle-income country with 
robust economic growth. However, the prioritisation of 
resources for TB control remains a major challenge. In 
this article, we highlight areas that urgently require ac-
tion to effectively reduce TB burden to minimal levels. 
Our conclusions suggest the need for fund allocation 
and a multidisciplinary approach to ensure prompt lab-
oratory diagnosis, treatment assurance and workforce re-
inforcement, complemented by applied and operational 
research, development and innovation. 
K E Y  W O R D S :  gross domestic product; diagnosis; ther-
apy; biomarker research; control programme
PANAMA still faces challenges in overcoming infec-
tious diseases, including tuberculosis (TB). In 2011, 
the incidence of all forms of TB remained at 38.6 per 
100 000 population.1 A steep decrease in the TB mor-
tality rate has been observed since 2009; however, 
Panama remains one of two countries with the high-
est TB mortality rates in Central America (Table 1).1 
Panama successfully reduced the percentage of new 
multidrug-resistant TB (MDR-TB) cases in 2011 to 
0.45%.1 Most TB cases, excluding patients co-infected 
with the human immunodefi ciency virus (HIV), are 
located in areas with low socio-economic develop-
ment, including Panama City, Colon City and indige-
nous populations.2,3 The main age category affected 
is those aged 25–49 years. However, this reality is in 
contrast with the country’s economic growth.
Dramatic economic growth has propelled Panama 
forward over the last 10 years; it is now the fastest 
growing economy in Central America.4 This growth 
has been possible due to the expansion of the Panama 
Canal and enormous investments in infrastructure by 
both the public and private sectors.5 Foreign invest-
ment has also increased due to Panama’s strong bank-
ing system and its strategic position as a trading hub 
with major logistic assets, including ports and duty-
free zones. The yearly average gross domestic prod-
uct growth for the 2007–2011 period was 9%, and it 
is estimated to continue to increase at 6% over the 
next 5 years (Table 2).5 These economic growth indi-
cators are expected to positively impact the country’s 
development in terms of education, health and safety. 
However, control of TB remains a major challenge 
yet to be addressed.
ASPECT OF INTEREST
TB control has major limitations in Panama. Al-
though the TB fi eld has seen advances in disease diag-
nosis over the last few years, laboratory diagnosis 
can take weeks, particularly in high-incidence lo-
cations. For example, the laboratory turnover time 
for acid-fast bacilli (AFB) smear results reached up to 
6 months in Colon City in early 2011. Remote areas 
such as indigenous territories lack facilities even min-
imally equipped to perform AFB smear microscopy. 
There is only one AFB laboratory in Guna Yala Co-
marca, which serves 32 500 people living along nearly 
100 km of coastal rural settlements, with limited ac-
cessibility. Moreover, there are frequent interruptions 
in anti-tuberculosis drug supplies. During 2010–2012, 
the cities of Colon and Panama experienced intermit-
tent availability of fi rst-line combined drugs; how-
ever, drug loans from other countries and provinces 
helped alleviate this need. This situation favours late 
anti-tuberculosis treatment initiation and reduced ad-
herence to the DOTS strategy. 
While MDR-TB is not a major issue, recent stud-
ies have demonstrated high transmission levels of 
S U M M A R Y
TB  control  and  economic  growth  in  Panama 287
resistant strains in the Panamanian population.6 Sim-
ilarly, the high turnover rate of health care workers 
limits development of the skills required to manage 
an integrated TB control programme. In 2012, Colon 
City reported up to four nursing staff changes at a 
given Social Security TB Clinic. Taken together, these 
factors have limited Panama’s ability to take adequate 
steps towards achieving the Millennium Develop-
ment Goal 6.C for TB control, i.e., to halve TB inci-
dence and mortality by 2015, especially in minimis-
ing the TB mortality rate. 
Financial commitment to TB control in Panama is 
still lacking. Limited success in reducing TB mortality 
has emerged from a lack of prioritised use of eco-
nomic resources. Panama’s domestic funding for TB 
decreased from US$1.8 million in 2008 to zero in 
2013.7 As a consequence, operations are ineffi cient in 
fi ve areas of TB control, including anti-tuberculosis 
treatment and drugs, laboratory network and quality 
assurance, high-risk groups, TB-HIV co-infection and 
TB in children. The National Secretariat of Science, 
Technology and Innovation recently approved a grant 
to reinforce one TB laboratory in Colon City, and the 
University Research Co., LLC, Bethesda, MD, USA, is 
conducting a programme to strengthen both TB and 
TB-HIV responses in Colon City and Panama City. 
Such support remains insuffi cient to strengthen TB 
control across the entire country. In contrast, El Sal-
vador has consistently assigned nearly US$4.0 mil-
lion annually to its national TB control programme,7 
resulting in a steady decrease in TB mortality. El Sal-
vador has also established routine drug susceptibil-
ity testing surveillance systems for all previously 
treated cases.7 We believe that similar domestic fund-
ing commitments within Central American countries 
and Panama will help defeat TB in the region. 
DISCUSSION
A strategy for controlling TB and minimising the 
TB mortality rate in Panama requires a few key 
steps that have already been identifi ed but that need 
strengthening.8,9 First, a decisive willingness to in-
crease d omestic and international funding for TB 
control through a multidisciplinary approach is nec-
essary. If resources are granted, funding efforts should 
be directed initially to reinforce and expand the TB 
laboratory network in Panama; specifi cally, new lab-
oratories are needed to perform AFB smear micros-
copy in Colon and indigenous territories. Second, 
novel strategies for TB drug purchasing and distribu-
tion should be implemented to sustain current treat-
ments and treat both new TB cases and MDR-TB pa-
tients. Drugs should be purchased using a 3-year 
supply contract model to guarantee drug availability 
over longer periods. Third, an increase in the number 
of health care workers dedicated exclusively to local 
TB control programmes could strengthen their roles 
in active search, diagnosis, treatment, contact inves-
tigation and data management. In addition to the so-
lutions proposed above, additional funding should 
come from collaborations between the private sector 
and governmental agencies to sponsor applied and 
operational research, development and innovation 
(RDI). RDI strategies will accelerate both improve-
ments in TB diagnosis as well as the identifi cation 
and correction of other issues that limit the opera-
tions of the TB control programme.7 Studies on novel 
Table 1 Annual tuberculosis mortality rate (incidence rate) in Central America, 2002–2012*
 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Belize 6.8 (40) 5.9 (40) 2.8 (40) 2.2 (40) 5.6 (40) 2.8 (40) 5.3 (40) 4.1 (40) 4.3 (40) 4.3 (40) 4.3 (40)
Guatemala 4.1 (67) 3.7 (66) 3.4 (65) 3.3 (65) 3.0 (64) 2.6 (63) 2.9 (63) 2.5 (62) 2.3 (62) 2.2 (61) 2.1 (60)
El Salvador 2.5 (38) 1.7 (33) 2.2 (32) 1.8 (39) 1.2 (34) 2.0 (33) 1.6 (32) 1.4 (30) 1.2 (28) 1.1 (27) 1.0 (25)
Honduras 4.5 (102) 4.2 (91) 4.0 (81) 3.8 (73) 3.7 (66) 3.5 (60) 3.4 (57) 3.2 (55) 3.1 (54) 3.0 (54) 2.9 (54)
Nicaragua 5.0 (62) 5.8 (59) 5.3 (56) 5.4 (53) 4.3 (51) 4.1 (49) 3.3 (46) 3.3 (44) 4.5 (42) 3.3 (40) 3.1 (38)
Costa Rica 1.8 (30) 1.7 (28) 1.6 (25) 1.4 (23) 1.2 (21) 0.8 (19) 1.2 (17) 1.1 (16) 0.9 (14) 0.8 (12) 0.8 (11)
Panama 6.0 (51) 7.1 (50) 5.8 (51) 6.3 (49) 5.9 (48) 4.9 (46) 5.7 (45) 6.3 (43) 5.1 (42) 4.3 (43) 5.2 (39)†
* Source: World Health Organization, Tuberculosis Global Report, 2013,7 and National Tuberculosis Control Programme in Panama.
† Estimated values for 2012.
Table 2 Annual estimated per cent change in GDP and absolute GDP (in billion USD) for Central American countries, 2002–2012*
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Belize 5.2 (0.9) 9.3 (1.0) 4.6 (1.1) 2.6 (1.1) 5.1 (1.2)  1.2 (1.3)  3.8 (1.4) −0.0 (1.3) 2.7 (1.4)  1.9 (1.5)  5.3 (1.6)
Costa Rica 2.9 (16.8) 6.4 (17.5) 4.3 (18.6) 5.9 (20.0) 8.8 (22.5)  7.9 (26.3)  2.7 (29.8) −1.0 (29.4) 4.7 (36.2)  4.2 (40.9)  5.0 (45.1)†
El Salvador 2.3 (14.3) 2.3 (15.0) 1.9 (15.8) 3.6 (17.1) 3.9 (18.6)  3.8 (20.1)  1.3 (21.4) −3.1 (20.7) 1.4 (21.4)  2.0 (23.1)  1.6 (23.8)†
Guatemala 3.9 (20.8) 2.5 (21.9) 3.2 (24.0) 3.3 (27.2) 5.4 (30.2)  6.3 (34.1)  3.3 (39.1)   0.5 (37.7) 2.9 (41.3)  4.1 (47.0)  3.0 (49.9)†
Honduras 3.8 (7.8) 4.5 (8.2) 6.2 (8.8) 6.1 (9.7) 6.6 (10.9)  6.2 (12.3)  4.2 (13.8) −2.4 (14.5) 3.7 (15.8)  3.7 (17.7)  3.3 (18.4)†
Nicaragua 0.8 (5.2) 2.5 (5.3) 5.3 (5.8) 4.3 (6.3) 4.2 (6.8)  5.0 (7.4)  4.0 (8.3) −2.2 (8.2) 3.6 (8.6)  5.4 (9.6)  5.2 (10.5)†
Panama 2.2 (12.3) 4.2 (12.9) 7.5 (14.2) 7.2 (15.7) 8.5 (17.1) 12.1 (19.8) 10.1 (23.0)   3.9 (24.2) 7.5 (27.1) 10.8 (31.3) 10.7 (36.3)
* Source: International Monetary Fund.4
† Estimated values for 2012.
GDP = gross domestic product; USD = US dollar.
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biomarkers for TB diagnosis and treatment monitor-
ing should also be implemented.10 
CONCLUSION
A multipronged approach to further reduce the TB 
mortality rate in Panama will require increased and 
prioritised resources within the action areas proposed 
here. Domestic and international funding is urgently 
needed to reinforce laboratory case detection, ensure 
treatment and employ permanent health care work-
ers for TB control. We believe that such a plan will 
favour the attainment of the Millennium Develop-
ment Goal for TB within an accelerated timeline. 
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La tuberculose (TB) est une maladie associée à l’absence 
d’équité et la lutte repose sur une utilisation judicieuse 
des ressources économiques. Le Panama a récemment 
obtenu le statut de pays à revenu moyen-supérieur avec 
une croissance économique solide. Cependant, la priori-
sation des ressources allouées à la lutte contre la TB 
reste un défi majeur. Dans ces notes émanant du terrain, 
nous mettons l’accent sur les domaines qui requièrent 
des efforts urgents afin de réduire efficacement le fardeau 
de la TB à son niveau le plus faible. Nos conclusions 
suggèrent qu’il est nécessaire d’allouer judicieusement 
les ressources et d’avoir une approche multidisciplinaire 
afin d’assurer un diagnostic de laboratoire rapide, une 
garantie de traitement et un renforcement du personnel, 
complétés par une activité de recherche, développement 
et innovation, appliquée et opérationnelle. 
La tuberculosis (TB) se asocia con la falta de equidad y 
se considera que una inversión razonable de los recursos 
económicos representa un factor primordial en el con-
trol de la enfermedad. En tiempos recientes, Panamá ha 
consolidado su posición como un país de recursos inter-
medios altos con un sólido crecimiento económico. Sin 
embargo, la priorización de los recursos destinados a 
la TB aun plantea dificultades importantes. En las pre-
sentes notas del terreno se pusieron de relieve las esferas 
que precisan medidas urgentes con el fin de disminuir 
eficazmente a un nivel mínimo la carga de la morbilidad 
por TB. Se destaca la necesidad de asignar recursos y es-
tablecer una estrategia multidisciplinaria que vele por el 
diagnóstico oportuno de laboratorio, la garantía del 
tratamiento y el fortalecimiento del personal, aunado a 
la investigación aplicada y operativa, el desarrollo y la 
innovación.
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